1. Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies
- Author
-
Takeshi Iwatsubo, K. Suzuki, Atsushi Iwata, Yuki Niimi, Tatsushi Toda, Ryoko Ihara, Tatsuo Mano, and Kenichiro Sato
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Amyloid beta ,Prodromal Symptoms ,Neuroimaging ,Japan ,Alzheimer Disease ,Internal medicine ,mental disorders ,medicine ,Dementia ,Humans ,Longitudinal Studies ,Aged ,Retrospective Studies ,biology ,business.industry ,Area under the curve ,Brain ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,United States ,Clinical trial ,Cohort ,biology.protein ,Female ,Alzheimer's disease ,business - Abstract
BACKGROUND: Models that can predict brain amyloid beta (Aβ) status more accurately have been desired to identify participants for clinical trials of preclinical Alzheimer’s disease (AD). However, potential heterogeneity between different cohorts and the limited cohort size have been the reasons preventing the development of reliable models applicable to the Asian population, including Japan. Objectives: We aim to propose a novel approach to predict preclinical AD while overcoming these constraints, by building models specifically optimized for ADNI or for J-ADNI, based on the larger samples from A4 study data. Design & Participants: This is a retrospective study including cognitive normal participants (CDR-global = 0) from A4 study, Alzheimer Disease Neuroimaging Initiative (ADNI), and Japanese-ADNI (J-ADNI) cohorts. Measurements: The model is made up of age, sex, education years, history of AD, Clinical Dementia Rating-Sum of Boxes, Preclinical Alzheimer Cognitive Composite score, and APOE genotype, to predict the degree of amyloid accumulation in amyloid PET as Standardized Uptake Value ratio (SUVr). The model was at first built based on A4 data, and we can choose at which SUVr threshold configuration the A4-based model may achieve the best performance area under the curve (AUC) when applied to the random-split half ADNI or J-ADNI subset. We then evaluated whether the selected model may also achieve better performance in the remaining ADNI or J-ADNI subsets. Result: When compared to the results without optimization, this procedure showed efficacy of AUC improvement of up to approximately 0.10 when applied to the models “without APOE;” the degree of AUC improvement was larger in the ADNI cohort than in the J-ADNI cohort. Conclusions: The obtained AUC had improved mildly when compared to the AUC in case of literature-based predetermined SUVr threshold configuration. This means our procedure allowed us to predict preclinical AD among ADNI or J-ADNI second-half samples with slightly better predictive performance. Our optimizing method may be practically useful in the middle of the ongoing clinical study of preclinical AD, as a screening to further increase the prior probability of preclinical AD before amyloid testing.
- Published
- 2021